Jointown Pharmaceutical Group reports strong semi-annual profit and revenue growth

Jointown Pharmaceutical Group’s 2025 semi-annual report highlights robust performance, with operating revenue growing by 5.10% to 811.06 bn yuan and net profit attributable to shareholders increasing by 19.70% to 14.46 bn yuan. This growth is attributed to strong performances in the pharmaceutical industrial and digital logistics sectors, which saw revenue increases of 10.77% and 24.66% respectively, alongside a 438 m yuan net profit boost from the public REITs listing of its pharmaceutical warehousing and logistics infrastructure.

The company's strategic focus on "New Products, New Retail, New Medical, Digitalization, and Real Estate Securitization" (the "Three New and Two Transformations" strategy) continues to yield positive results. Despite a 19.34% decrease in non-recurring net profit attributable to shareholders due to increased impairment provisions for epidemic prevention materials and extended hospital payment terms, operating cash flow improved by 3.8 bn yuan due to enhanced accounts receivable collection efforts.

Jointown also announced a 2025 semi-annual performance briefing for September 3, 2025, to discuss these results and strategic progress with investors. Concurrently, the company announced a provision of 37,830.40 m yuan for credit impairment and asset impairment, impacting the consolidated pre-tax profit by the same amount for the first half of 2025.